Join AIML’s Live Shareholder Update with Chairman & CEO Paul Duffy

• A Look Back at Key Milestones and Successes Achieved in 2025

• What’s Ahead: Exciting Plans, Strategic Outlook, and Goals for 2026

• Advancing the Next Phase of Commercialization

TORONTO, ON / ACCESS Newswire / December 16, 2025 / AI/ML Innovations Inc. (“AIML” or the “Company”) (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to invite shareholders and stakeholders to join an upcoming Livestream Company Update, hosted by Chairman and CEO Paul Duffy.

The livestream event will provide an overview of AIML’s key achievements from 2025, along with a preview of exciting milestones planned for the first 90 days of 2026. Shareholders will have the opportunity to hear firsthand how AIML is executing on its commercialization strategy and driving growth across its portfolio of AI-powered healthcare technologies.

Event Details:

Date: Thursday, December 18, 2025
Time: 4pm Eastern Standard Time
Access Link: Zoom Link

“We’ve had a strong 2025 that marked the beginning of commercialization through several pilot programs, and we’re encouraged by the progress we’ve made,” said Chairman and CEO, Paul Duffy. “As we look ahead to 2026, our focus is on continuing to aggressively pursue further commercialization while advancing our regulatory approval pathways. This livestream is an opportunity to connect with our shareholders around our vision, our execution strategy, and the important work we’re doing to bring AI-driven health innovation to market.

Shareholders are encouraged to attend and participate in this interactive session to gain deeper insight into AIML’s trajectory and future opportunities. If you would like to pre-submit questions as part of the livestream, please email them to Ask@aiml.health.

About AI/ML Innovations Inc.

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.

AIML’s shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

For detailed information please see AIML’s website or the Company’s filed documents at www.sedarplus.ca .

Contact:
Blake Fallis (778) 405-0882

On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements – Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company’s products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

SOURCE: AI/ML Innovations, Inc.

View the original press release on ACCESS Newswire